Literature DB >> 21390186

Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells.

Karin Haim1, Polina Weitzenfeld, Tsipi Meshel, Adit Ben-Baruch.   

Abstract

The tumor microenvironment contains multiple cancer-supporting factors, whose joint activities promote malignancy. Here, we show that epidermal growth factor (EGF) and estrogen upregulate in an additive manner the transcription and the secretion of the angiogenic chemokine CXCL8 (interleukin 8 [IL-8]) in breast tumor cells. In view of published findings on cross-regulatory interactions between EGF receptors and estrogen receptors in breast tumor cells, we asked whether the additive effects of EGF and estrogen were due to their ability to (1) induce intracellular cross talk and amplify shared regulatory pathways or (2) act in independent mechanisms, which complement each other. We found that stimulation by EGF alone induced the release of CXCL8 through signaling pathways involving ErbB2, ErbB1, Erk, and phosphoinositide 3-kinase (PI3K). ErbB2 and Erk were also involved in estrogen activities on CXCL8 but to a lower extent than with EGF. However, in the joint stimulatory setup, the addition of estrogen to EGF has led to partial (ErbB2, ErbB1, Erk) or complete (PI3K) shutoff of the involvement of these activation pathways in CXCL8 up-regulation. Furthermore, when costimulation by EGF + estrogen was applied, the effects of estrogen were channeled to regulation of CXCL8 at the transcription level, acting through the transcription factor estrogen receptor α (ERα). In parallel, in the joint stimulation, EGF acted independently at the transcription level through AP-1, to upregulate CXCL8 expression. The independent activities of EGF and estrogen on CXCL8 transcription reinforce the need to introduce simultaneous targeting of ErbBs and ERα to achieve effective therapy in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21390186      PMCID: PMC3050866          DOI: 10.1593/neo.101340

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  58 in total

Review 1.  EGF-ERBB signalling: towards the systems level.

Authors:  Ami Citri; Yosef Yarden
Journal:  Nat Rev Mol Cell Biol       Date:  2006-07       Impact factor: 94.444

2.  A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.

Authors:  Wenle Xia; Sarah Bacus; Priti Hegde; Intisar Husain; Jay Strum; Leihua Liu; Georgina Paulazzo; Ljuba Lyass; Patricia Trusk; Jason Hill; Jennifer Harris; Neil L Spector
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

Review 3.  Potential role of estrogen receptor alpha (ERalpha) phosphorylated at Serine118 in human breast cancer in vivo.

Authors:  Leigh C Murphy; G E Weitsman; G P Skliris; E M Teh; Lin Li; B Peng; J R Davie; K Ung; Y-L Niu; S Troup; L Tomes; P H Watson
Journal:  J Steroid Biochem Mol Biol       Date:  2006-11-07       Impact factor: 4.292

Review 4.  The role of the EGFR signaling in tumor microenvironment.

Authors:  Antonella De Luca; Adele Carotenuto; Annamaria Rachiglio; Marianna Gallo; Monica R Maiello; Donatella Aldinucci; Antonio Pinto; Nicola Normanno
Journal:  J Cell Physiol       Date:  2008-03       Impact factor: 6.384

5.  Role of interleukin-8 in the progression of estrogen receptor-negative breast cancer.

Authors:  Chen Yao; Ying Lin; Cai-sheng Ye; Jiong Bi; Yi-fan Zhu; Shen-ming Wang
Journal:  Chin Med J (Engl)       Date:  2007-10-20       Impact factor: 2.628

6.  CXC chemokines located in the 4q21 region are up-regulated in breast cancer.

Authors:  Ivan Bièche; Carine Chavey; Catherine Andrieu; Muriel Busson; Sophie Vacher; Ludovic Le Corre; Jean-Marc Guinebretière; Sandrine Burlinchon; Rosette Lidereau; Gwendal Lazennec
Journal:  Endocr Relat Cancer       Date:  2007-12       Impact factor: 5.678

7.  Oestrogen receptor negative breast cancers exhibit high cytokine content.

Authors:  Carine Chavey; Frédéric Bibeau; Sophie Gourgou-Bourgade; Sandrine Burlinchon; Florence Boissière; Daniel Laune; Sylvie Roques; Gwendal Lazennec
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

8.  Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells.

Authors:  Chen Yao; Ying Lin; Mei-Sze Chua; Cai-Sheng Ye; Jiong Bi; Wen Li; Yi-Fan Zhu; Shen-Ming Wang
Journal:  Int J Cancer       Date:  2007-11-01       Impact factor: 7.396

Review 9.  Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer.

Authors:  Stephen R D Johnston; Lesley-Ann Martin; Alex Leary; Julia Head; Mitch Dowsett
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-24       Impact factor: 4.292

Review 10.  Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy.

Authors:  Ido Amit; Ron Wides; Yosef Yarden
Journal:  Mol Syst Biol       Date:  2007-12-04       Impact factor: 11.429

View more
  14 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

3.  Interleukin 8 in progression of hormone-dependent early breast cancer.

Authors:  Jelena Milovanovic; Natasa Todorovic-Rakovic; Tijana Vujasinovic; Zaki Abu Rabi
Journal:  J Biosci       Date:  2017-06       Impact factor: 1.826

4.  Direct, interferon-independent activation of the CXCL10 promoter by NF-κB and interferon regulatory factor 3 during hepatitis C virus infection.

Authors:  Jessica Brownell; Jacob Bruckner; Jessica Wagoner; Emmanuel Thomas; Yueh-Ming Loo; Michael Gale; T Jake Liang; Stephen J Polyak
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

Review 5.  Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer.

Authors:  Jessica Brownell; Stephen J Polyak
Journal:  Clin Cancer Res       Date:  2013-01-15       Impact factor: 12.531

Review 6.  Interleukin-8 in breast cancer progression.

Authors:  Nataša Todorović-Raković; Jelena Milovanović
Journal:  J Interferon Cytokine Res       Date:  2013-05-22       Impact factor: 2.607

7.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

8.  Characteristics of chemokine signatures elicited by EGF and TNF in ovarian cancer cells.

Authors:  Deok-Soo Son; Syeda M Kabir; Yuanlin Dong; Eunsook Lee; Samuel E Adunyah
Journal:  J Inflamm (Lond)       Date:  2013-06-25       Impact factor: 4.981

9.  Progression of luminal breast tumors is promoted by ménage à trois between the inflammatory cytokine TNFα and the hormonal and growth-supporting arms of the tumor microenvironment.

Authors:  Polina Weitzenfeld; Nurit Meron; Tal Leibovich-Rivkin; Tsipi Meshel; Adit Ben-Baruch
Journal:  Mediators Inflamm       Date:  2013-12-04       Impact factor: 4.711

Review 10.  The role of chemokines in breast cancer pathology and its possible use as therapeutic targets.

Authors:  M Isabel Palacios-Arreola; Karen E Nava-Castro; Julieta I Castro; Eduardo García-Zepeda; Julio C Carrero; Jorge Morales-Montor
Journal:  J Immunol Res       Date:  2014-08-05       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.